Glioblastoma multiforme: Pathogenesis and treatment

Agarwal, 2012, Active efflux of dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly-targeted agents, Mol Cancer Ther, 11, 2183, 10.1158/1535-7163.MCT-12-0552 Ahluwalia, 2011, 2010 Society for Neuro-Oncology Annual meeting: a report of selected studies, Expert Rev Anticancer Ther, 11, 161, 10.1586/era.10.227 Alexander, 2013, A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly diagnosed glioblastoma (RTOG 9806), J Neurooncol, 111, 33, 10.1007/s11060-012-0987-0 Alvarez, 2015, The effects of histone deacetylase inhibitors on glioblastoma derived cells, J Mol Neurosci, 55, 7, 10.1007/s12031-014-0329-0 Alves, 2011, Glioblastoma cells: a heterogenous and fatal tumor interacting with the parenchyma, Life Sci, 89, 532, 10.1016/j.lfs.2011.04.022 Arora, 2005, Role of tyrosine kinase inhibitors in cancer therapy, J Pharmacol Exp Ther, 315, 971, 10.1124/jpet.105.084145 Arrieta, 2008, Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis, Br J Cancer, 99, 160, 10.1038/sj.bjc.6604431 Asklund, 2012, Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors, Anticancer Res, 32, 2407 Balcaitis, 2005, Lentiviral transduction of microglial cells, Glia, 50, 48, 10.1002/glia.20146 Baltuch, 1993, Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen, Neurosurgery, 33, 495, 10.1227/00006123-199309000-00021 Bao, 2008, Targeting cancer stem cells through L1CAM suppresses glioma growth, Cancer Res, 68, 6043, 10.1158/0008-5472.CAN-08-1079 Bao, 2006, Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor, Cancer Res, 66, 7843, 10.1158/0008-5472.CAN-06-1010 Bar, 2007, Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma, Stem Cells, 25, 2524, 10.1634/stemcells.2007-0166 Batchelor, 2010, Phase II study of cediranib, an oral pan-vasular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma, J Clin Oncol, 28, 2817, 10.1200/JCO.2009.26.3988 Berdelle, 2011, Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer, Mol Cancer Ther, 10, 2224, 10.1158/1535-7163.MCT-11-0534 Berezowska, 2011, Targeting ErbB receptors in high-grade glioma, Curr Pharm Des, 17, 2468, 10.2174/138161211797249233 Bhat, 2002, Adenovirus infection induces microglial activation: involvement of mitogen-activated protein kinase pathways, Brain Res, 948, 93, 10.1016/S0006-8993(02)02953-0 Bogdahn, 2011, Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study, Neuro Oncol, 13, 132, 10.1093/neuonc/noq142 Brandes, 2010, EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/XK222584 (PTK/ZK) in newly diagnosed glioblastoma, Eur J Cancer, 46, 348, 10.1016/j.ejca.2009.10.029 Buchanan, 2009, SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo, Mol Cancer Ther, 8, 3181, 10.1158/1535-7163.MCT-09-0477 Buchanan, 2011, Radiosensitization of glioma cells by modulation of Met signaling with the hepatocyte growth factor neutralizing antibody, AMG102, J Cell Mol Med, 15, 1999, 10.1111/j.1582-4934.2010.01122.x Butowski, 2011, Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma, Neuro Oncol, 13, 1331, 10.1093/neuonc/nor130 Butowski, 2009, A North American brain tumor consortium phase II study of Poly-ICLC for adult patients with recurrent anaplastic gliomas, J Neurooncol, 91, 183, 10.1007/s11060-008-9705-3 Butowski, 2006, Diagnosis and treatment of recurrent high-grade astrocytoma, J Clin Oncol, 24, 1273, 10.1200/JCO.2005.04.7522 Carrillo, 2012, Alternative chemotherapeutic agents: nitrosureas, cisplatin, irinotecan, Neurosurg Clin N Am, 23, 297, 10.1016/j.nec.2012.01.005 Chakravanti, 2004, The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas, J Clin Oncol, 22, 1926, 10.1200/JCO.2004.07.193 Chang, 2005, Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme, Invest New Drugs, 23, 357, 10.1007/s10637-005-1444-0 Chaponis, 2011, Lonafanib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas, J Neurooncol, 104, 179, 10.1007/s11060-010-0502-4 Charles, 2011, The brain tumor microenvironment, Glia, 59, 1169, 10.1002/glia.21136 Chen, 2013, The efficacy of temozolomide for recurrent glioblastoma multiforme, Eur J Neurol, 20, 223, 10.1111/j.1468-1331.2012.03778.x Cheng, 2013, Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth, Cell, 153, 139, 10.1016/j.cell.2013.02.021 Cheng, 2013, IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis, Tumour Biol, 34, 3555-3359, 10.1007/s13277-013-0934-5 Chi, 2012, Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor, J Clin Oncol, 30, e30, 10.1200/JCO.2011.38.4586 Chinot, 2001, Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy, J Clin Oncol, 19, 2449, 10.1200/JCO.2001.19.9.2449 Choi, 2014, Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma, J Clin Neurosci, 21, 189, 10.1016/j.jocn.2013.03.012 Choy, 2012, Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers, Cancer Chemother Pharmacol, 70, 183, 10.1007/s00280-012-1821-2 Clarke, 2009, Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma, J Clin Oncol, 27, 3861, 10.1200/JCO.2008.20.7944 Clement, 2007, HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity, Curr Biol, 17, 165, 10.1016/j.cub.2006.11.033 Cloughesy, 2006, Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing anti-epileptic drugs: a North American Brain Tumor Consortium Study, J Clin Oncol, 24, 3651, 10.1200/JCO.2006.06.2323 Curran, 1993, Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials, J Natl Cancer Inst, 85, 704, 10.1093/jnci/85.9.704 De Faria, 2008, Differences in the expression pattern of P-glycoproteins and MRP1 in low-grade and hogh-grade gliomas, Cancer Invest, 26, 883, 10.1080/07357900801975264 De Fazio, 2012, Efficacy and safety of bevacizumab in glioblastomas, Curr Med Chem, 19, 972, 10.2174/092986712799320646 de Groot, 2011, Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study, J Clin Oncol, 29, 2689, 10.1200/JCO.2010.34.1636 de Groot, 2011, Glutamate and the biology of gliomas, Glia, 59, 1181, 10.1002/glia.21113 De la Pena, 2006, Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells, Mol Cancer Ther, 5, 1504, 10.1158/1535-7163.MCT-06-0091 Dean, 2005, Tumour stem cells and drug resistance, Nat Rev Cancer, 5, 275, 10.1038/nrc1590 Deeks, 2014, Nivolumab: a review of its use in patients with malignant melanoma, Drugs, 74, 1233, 10.1007/s40265-014-0234-4 Del Vecchio, 2012, Targeting EGF receptor variant III: tumor specific peptide vaccination for malignant gliomas, Expert Rev Vaccines, 11, 133, 10.1586/erv.11.177 Desjardins, 2011, A phase I trial of the farnesyltransferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma, J Neurooncol, 105, 601, 10.1007/s11060-011-0627-0 di Tomaso, 2009, PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment, PLoS One, 4, 10.1371/journal.pone.0005123 Dillman, 2009, Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma, J Immunother, 32, 914, 10.1097/CJI.0b013e3181b2910f Dixit, 2009, Manumycin inhibits STAT3, telomerase activity, and growth of glioma cells by elevating intracellular reactive oxygen species generation, Free Radic Biol Med, 47, 364, 10.1016/j.freeradbiomed.2009.04.031 Drappatz, 2013, Phase I study of GRN1005 in recurrent malignant glioma, Clin Cancer Res, 19, 1567, 10.1158/1078-0432.CCR-12-2481 Drappatz, 2012, Phase I study of panobinostat in combination with bevacizumab for recurrent high grade glioma, J Neurooncol, 107, 133, 10.1007/s11060-011-0717-z Drappatz, 2009, A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme, Int J Radiat Oncol Biol Phys, 73, 222, 10.1016/j.ijrobp.2008.03.046 Dresemann, 2010, Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide, J Neurooncol, 96, 393, 10.1007/s11060-009-9976-3 Du, 2012, Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway, World J Surg Oncol, 10, 60, 10.1186/1477-7819-10-60 Ducassou, 2013, αvβ3 integrin and fibroblast growth factor receptor 1 (FGFR1): prognostic factors in a phase I-II clinical trial associating continuous administration of tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma, Eur J Cancer, 49, 2161, 10.1016/j.ejca.2013.02.033 Efferth, 2004, Combination treatment of glioblastoma multiforme cell lines with the antimalarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774, Biochem Pharmacol, 67, 1689, 10.1016/j.bcp.2003.12.035 Eisenstat, 2011 Esteller, 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, N Engl J Med, 343, 1350, 10.1056/NEJM200011093431901 Facchino, 2011, Brain cancer stem cells: Current status on glioblastoma multiforme, Cancers, 3, 1777, 10.3390/cancers3021777 Fadul, 2008, A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme, J Neurooncol, 90, 229, 10.1007/s11060-008-9655-9 Fakhrai, 2006, Phase I clinical trial of TGF-beta antisense-modified tumor cell vaccine in patients with advanced gliioma, Cancer Gene Ther, 13, 1052, 10.1038/sj.cgt.7700975 Fan, 2006, A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma, Cancer Cell, 9, 341, 10.1016/j.ccr.2006.03.029 Farrell, 2007, Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau and other syndromes, Neurol Clin, 25, 925, 10.1016/j.ncl.2007.07.008 Ferrara, 2005, VEGF as a therapeutic target in cancer, Oncology, 69, 11, 10.1159/000088479 Ferruzzi, 2012, In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines, Int J Cancer, 131, E33, 10.1002/ijc.27349 Fields, 2012, Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas, Int J Radiat Oncol Biol Phys, 82, 51, 10.1016/j.ijrobp.2010.09.008 Fine, 2007, A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors, Clin Cancer Res, 13, 7101, 10.1158/1078-0432.CCR-07-1546 Fisher, 2007, Epidemiology of brain tumors, Neurol Clin, 25, 867, 10.1016/j.ncl.2007.07.002 Floyd, 2012, Alpha secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch, Neuro Oncol, 14, 1215, 10.1093/neuonc/nos157 Fouladi, 2011, Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric consortium study, J Clin Oncol, 29, 3529, 10.1200/JCO.2011.35.7806 Franceschi, 2012, EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma, Neuro Oncol, 14, 1503, 10.1093/neuonc/nos256 Friday, 2012, Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study, Neuro Oncol, 14, 215, 10.1093/neuonc/nor198 Friedman, 2009, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol, 27, 4733, 10.1200/JCO.2008.19.8721 Fu, 2013, NPV-LDE-225 (Erismodegib) inhibits mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200, Neuro Oncol, 15, 691, 10.1093/neuonc/not011 Fukai, 2008, Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III, Cancer Sci, 99, 2062 Furnari, 2007, Malignant astrocytic glioma: genetics, biology and paths to treatment, Genes Dev, 21, 2683, 10.1101/gad.1596707 Galanis, 2005, Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study, J Clin Oncol, 23, 5294, 10.1200/JCO.2005.23.622 Galanis, 2009, Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study, J Clin Oncol, 27, 2052, 10.1200/JCO.2008.19.0694 Gan, 2009, Sunitinib in solid tumors, Expert Opin Investig Drugs, 18, 821, 10.1517/13543780902980171 Gaspar, 2009, Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells, Cancer Res, 69, 1966, 10.1158/0008-5472.CAN-08-3131 Gilbert, 2014, A randomized trial of bevacizumab for newly diagnosed glioblastoma, N Engl J Med, 370, 699, 10.1056/NEJMoa1308573 Gilbert, 2006, A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarazar, SCH66336) in recurrent glioblastoma.2006 ASCO Annual Meeting Procedings Part I, J Clin Oncol, 24, 1556, 10.1200/jco.2006.24.18_suppl.1556 Gilbert, 2012, Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery, J Neurooncol, 106, 147, 10.1007/s11060-011-0650-1 Gilbert, 2010, RTOG 0635: A randomized phase II trial of bevacizumab with either irinotecan (CPT) or dose-dense temozolomide (TMZ) in recurrent glioblastoma (GBM), Neuro Oncol, 12, iv36 Gini, 2013, The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas, Clin Cancer Res, 19, 5722, 10.1158/1078-0432.CCR-13-0527 Giordano, 2009, Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer, Curr Opin Mol Ther, 11, 288 Glass, 1992, The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy, J Neurosurg, 75, 741, 10.3171/jns.1992.76.5.0741 Glen, 2011, E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion, BMC Cancer, 11, 309, 10.1186/1471-2407-11-309 Gomez-Manzano, 2008, VEGF Trap induces antiglioma effect at different stages of disease, Neuro Oncol, 10, 940, 10.1215/15228517-2008-061 Green, 1983, Comparisons of carmustine, procarbazine, and high dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma, Cancer Treat Rep, 67, 121 Greenall, 2014, Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo, Oncogene, 106 Grossman, 2009, Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme: a multicenter phase II trial, J Clin Oncol, 27, 4155, 10.1200/JCO.2008.21.6895 Gruber, 2009, Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progression-free survival, overall survival, and toxicity, J Clin Oncol, 27, 2017, 10.1200/jco.2009.27.15_suppl.2017 Guan, 2011, Sorafenib: activity and clinical application in patients with hepatocellular carcinoma, Expert Opin Pharmacother, 12, 303, 10.1517/14656566.2011.546346 Guessous, 2010, An orally available c-Mat kinase inhibitor potently inhibits brain tumor malignancy and growth, Anticancer Agents Med Chem, 10, 28, 10.2174/1871520611009010028 Guryanova, 2011, Non-receptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3, Cancer Cell, 19, 498, 10.1016/j.ccr.2011.03.004 Haas-Kogan, 2005, Biomarkers to predict response to epidermal growth factor receptor inhibitors, Cell Cycle, 4, 1369, 10.4161/cc.4.10.2105 Haas-Kogan, 2005, Epidermal growth factor receptor protein kinase B/Akt, and glioma response to erlotinib, J Natl Cancer Inst, 97, 880, 10.1093/jnci/dji161 Hainsworth, 2010, Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme, Cancer, 116, 3663, 10.1002/cncr.25275 Hainsworth, 2012, Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab, followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma, Clin Adv Hematol Oncol, 10, 240 Hardell, 2007, Long-term use of cellular phones and brain tumors: increased risk associated with use for>or=10years, Occup Environ Med, 64, 626, 10.1136/oem.2006.029751 Harris, 2004, Monoclonal antibodies as therapeutic agents for cancer, Lancet Oncol, 5, 292, 10.1016/S1470-2045(04)01467-6 Hartmann, 2010, Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas, Acta Neuropathol, 120, 707, 10.1007/s00401-010-0781-z Hasselbalch, 2010, Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial, Neuro Oncol, 12, 508 Hau, 2011, TGF-β2 signalling in high grade gliomas, Curr Pharm Biotechnol, 12, 2150, 10.2174/138920111798808347 Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, 352, 997, 10.1056/NEJMoa043331 Held-Feindt, 2012, The neural adhesion molecule L1CAM confers chemoresistance in human glioblastomas, Neurochem Int, 61, 1183, 10.1016/j.neuint.2012.08.011 Hiddingh, 2014, EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma, Oncotarget, 5, 363, 10.18632/oncotarget.1620 Hirai, 2010, MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents ormolecular targeted drugs in vitro and in vivo, Mol Cancer Ther, 9, 1956, 10.1158/1535-7163.MCT-09-1012 Höring, 2013, The histone deacetylase inhibitor trichostatin A promotes apoptosis and antitumor immunity in glioblastoma cells, Anticancer Res, 33, 1351 Hsu, 2009, Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy, BioDrugs, 23, 289, 10.2165/11317600-000000000-00000 Hua, 2011, CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma, J Neurooncol, 105, 149, 10.1007/s11060-011-0572-y Hussain, 2007, A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients, Cancer Res, 67, 9630, 10.1158/0008-5472.CAN-07-1243 Huveldt, 2013, Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion, PLoS One, 8, e56505, 10.1371/journal.pone.0056505 Iwamoto, 2010, Phase II trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas, Cancer, 117, 1776, 10.1002/cncr.24957 Iwamoto, 2011, A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03, Neuro Oncol, 13, 509, 10.1093/neuonc/nor017 Iwamoto, 2010, Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02), Neuro Oncol, 12, 855, 10.1093/neuonc/noq025 Jabbour, 2012, Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management, Am J Hematol, 87, 1037, 10.1002/ajh.23282 Jackson, 2013, Vaccine strategies for glioblastoma: progress and future directions, Immunotherapy, 5, 155, 10.2217/imt.12.155 Jain, 2007, Angiogenesis in brain tumours, Nat Rev Neurosci, 8, 610, 10.1038/nrn2175 Jiang, 2007, Examination of the therapeutic potential of Delta-24-RGD in brain tumor cells: role of autophagic cell death, J Natl Cancer Inst, 99, 1410, 10.1093/jnci/djm102 Jo, 2012, Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms, Mol Med Rep, 6, 88 Joensuu, 2005, Amplification of genes encoding KIT, PDGFRα and VGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme, J Pathol, 207, 224, 10.1002/path.1823 Johns, 2012, MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor, Int J Radiat Oncol Biol Phys, 78, 572, 10.1016/j.ijrobp.2010.03.027 Kang, 2008, Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety, J Neurooncol, 89, 113, 10.1007/s11060-008-9599-0 Karavasilis, 2013, A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas, J Neurol, 260, 1469, 10.1007/s00415-012-6812-z Karimkhari, 2014, A review of novel therapies for melanoma, Am J Clin Dermatol, 15, 323, 10.1007/s40257-014-0083-7 Kast, 2010, Glioblastoma invasion, cathepsin B, and the potential for both to be inhibited by auranofin, an old anti-rhematoid arthritis drug, Cen Eur Neurosurg, 71, 139, 10.1055/s-0029-1242756 Kast, 2013, A conceptually new treatment approach for relapsed glioblastoma: Coordinated Undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care, Oncotarget, 4, 502, 10.18632/oncotarget.969 Kast, 2012, Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma, Arch Med Res, 43, 243, 10.1016/j.arcmed.2012.04.005 Kitange, 2012, Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts, Clin Cancer Res, 18, 4070, 10.1158/1078-0432.CCR-12-0560 Kleihues, 1999, Primary and secondary glioblastomas: from concept to clinical diagnosis, Neuro Oncol, 1, 44, 10.1093/neuonc/1.1.44 Knobbe, 2004, Mutation analysis of the RAS pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas, Acta Neuropathol, 108, 467, 10.1007/s00401-004-0929-9 Koso, 2012, Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells, Proc Natl Acad Sci U S A, 109, E2998, 10.1073/pnas.1215899109 Koul, 2012, Antitumor activity of NVP-BKM120 – a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells, Clin Cancer Res, 18, 184, 10.1158/1078-0432.CCR-11-1558 Krashraw, 2010, Advances in the treatment of malignant gliomas, Curr Oncol Rep, 12, 26, 10.1007/s11912-009-0077-4 Krebs, 2014, T cells redirected to interleukin-13Ra2 with interleukin-13-mutein-chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ra1, Cytotherapy, 16, 1121, 10.1016/j.jcyt.2014.02.012 Kreisl, 2010, A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas, Neuro Oncol, 12, 181, 10.1093/neuonc/nop042 Kreisl, 2009, Phase II trial of single-agent bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, J Clin Oncol, 27, 740, 10.1200/JCO.2008.16.3055 Kreisl, 2012, A phase I/II trial of vandetanib for patients with recurrent malignant glioma, Neuro Oncol, 14, 1519, 10.1093/neuonc/nos265 Lai, 2009, Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme, J Clin Oncol, 27, 2000, 10.1200/jco.2009.27.15_suppl.2000 Lal, 2005, Targeting the c-Met pathway potentiates glioblastoma responses to gamma-irradiation, Clin Cancer Res, 11, 4479, 10.1158/1078-0432.CCR-05-0166 Langone, 2013, Coupling to a glioblastoma-directed antibody potentiates anti-tumor activity of curcumin, Int J Cancer, 135, 710, 10.1002/ijc.28555 Lathia, 2010, Integrin alpha 6 regulates glioblastoma stem cells, Cell Stem Cell, 6, 421, 10.1016/j.stem.2010.02.018 Lee, 2012, Phase I Study of Vorinostat in combination with Temozolomide in patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03. 2012, Clin Cancer Res, 18, 6032, 10.1158/1078-0432.CCR-12-1841 Lehky, 2011, Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome, Neurology, 76, 236, 10.1212/WNL.0b013e3182074a69 Leonard, 2013, Etoposide improves survival in high-grade glioma: a meta-analysis, Anticancer Res, 33, 3307 Lesniak, 2011, Immunotherapy for glioblastoma: the devil is in the details, J Clin Oncol, 29, 3105, 10.1200/JCO.2011.34.9019 Li, 2009, Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy, Mol Cancer Ther, 8, 376, 10.1158/1535-7163.MCT-08-0627 Liang, 2014, The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival, Med Oncol, 31, 122, 10.1007/s12032-014-0122-5 Lin, 2010, γ-secretase inhibitor-I enhances radiosensitivity of glioblastoma cell lines by depleting CD133+ tumor cells, Arch Med Res, 41, 519, 10.1016/j.arcmed.2010.10.006 Linnet, 2008, A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs, Eur Neuropsychopharmacol, 18, 157, 10.1016/j.euroneuro.2007.06.003 Liu, 2005, Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy, Oncogene, 24, 5226, 10.1038/sj.onc.1208519 Liu, 2011, Mosaic analysis with double markers reveals tumor cell of origin in glioma, Cell, 146, 209, 10.1016/j.cell.2011.06.014 Longo, 2012, Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant glioma brain tumor models, Invest New Drugs, 30, 2161, 10.1007/s10637-011-9784-4 Louis, 2006, Molecular pathology of malignant gliomas, Annu Rev Pathol, 1, 97, 10.1146/annurev.pathol.1.110304.100043 Louis, 2007, The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol, 114, 97, 10.1007/s00401-007-0243-4 Lu-Emerson, 2011, Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure, J Neurooncol, 104, 287, 10.1007/s11060-010-0489-x Lun, 2012, Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin, Cancer Res, 70, 598, 10.1158/0008-5472.CAN-09-1510 Lustig, 2008, Phase II preradiation R115777 in newly diagnosed GBM with residual enhancing disease, Neuro Oncol, 10, 1004, 10.1215/15228517-2008-070 Lv, 2012, Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab, Int J Oncol, 41, 1029, 10.3892/ijo.2012.1539 MackDonald, 2011, Treatment of high-grade glioma in children and adolescents, Neuro Oncol, 13, 1049, 10.1093/neuonc/nor092 Majumdar, 2009, Platelet-derived growth factor expression correlates with tumor grade and proliferative activity in human oligodendrogliomas, Surg Neurol, 72, 54, 10.1016/j.surneu.2008.10.001 Mallon, 2011, Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor, Clin Cancer Res, 17, 3193, 10.1158/1078-0432.CCR-10-1694 Mani, 2005, The ubiquitin-proteasome pathway and its role in cancer, J Clin Oncol, 23, 4776, 10.1200/JCO.2005.05.081 Manmeet, 2010, Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies, Cancer Lett, 298, 139, 10.1016/j.canlet.2010.08.014 Martens, 2006, A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo, Clin Cancer Res, 12, 6144, 10.1158/1078-0432.CCR-05-1418 Mason, 2012, A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression, J Neurooncol, 107, 343, 10.1007/s11060-011-0747-6 McCarty, 1997, Thalidomide may impede cell migration in primates by down-regulating integrin beta chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis, Med Hypotheses, 49, 123, 10.1016/S0306-9877(97)90217-6 Meiss, 2014, Vismodegib, Recent Results Cancer Res, 201, 405, 10.1007/978-3-642-54490-3_25 Mellinhoff, 2005, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors, N Engl J Med, 353, 2012, 10.1056/NEJMoa051918 Mendelsohn, 2006, Epidermal growth factor receptor targeting in cancer, Semin Oncol, 33, 369, 10.1053/j.seminoncol.2006.04.003 Mendiburu-Eliçabe, 2014, Efficacy of rapamycin against glioblastoma cancer stem cells, Clin Transl Oncol, 16, 495, 10.1007/s12094-013-1109-y Michelakis, 2010, Metabolic modulation of glioblastoma with dichloroacetate, Sci Transl Med, 2, 31ra34, 10.1126/scitranslmed.3000677 Mitchell, 2009, Toward effective immunotherapy for the treatment of malignant brain tumors, Neurotherapeutics, 6, 527, 10.1016/j.nurt.2009.04.003 Møller, 2013, A systematic review of MicroRNA in glioblastoma multiforme: Micro-modulators in the mesenchymal mode of migration and invasion, Mol Neurobiol, 47, 131, 10.1007/s12035-012-8349-7 Momota, 2005, Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo, Cancer Res, 65, 7429, 10.1158/0008-5472.CAN-05-1042 Muñoz, 2012, NK-1 receptor antagonists: a new generation of anticancer drugs, Mini Rev Chem, 12, 593, 10.2174/138955712800626692 Munoz, 2014, Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells, Mol Cancer Ther, 13, 2399, 10.1158/1535-7163.MCT-14-0011 Nabors, 2012, A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306), Cancer, 118, 5601, 10.1002/cncr.27585 Nagane, 2012, Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma, Jpn J Clin Oncol, 42, 887, 10.1093/jjco/hys121 Nagpal, 2012, The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma, Neurosurg Clin N Am, 23, 289, 10.1016/j.nec.2012.01.004 Nair, 2014, Immunological targeting of cytomegalovirus for glioblastoma therapy, OncoImmunology, 25, e29289, 10.4161/onci.29289 Nduom, 2012, Glioblastoma cancer stem-like cells – implications for pathogenesis and treatment, Cancer J, 18, 100, 10.1097/PPO.0b013e3182452e0d Neyns, 2011, Phase II study of sunitinib malate in patients with recurrent high-grade glioma, J Neurooncol, 103, 491, 10.1007/s11060-010-0402-7 Neyns, 2009, Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma, Ann Oncol, 20, 1596, 10.1093/annonc/mdp032 Nghiempu, 2011, A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma, Int J Radiat Oncol Biol Phys, 81, 1422, 10.1016/j.ijrobp.2010.07.1997 Ohgaki, 2013, The definition of primary and secondary glioblastoma, Clin Cancer Res, 19, 764, 10.1158/1078-0432.CCR-12-3002 Okada, 2007, Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas, J Transl Med, 5, 67, 10.1186/1479-5876-5-67 Onishi, 2013, Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme, Neurol Med Chir (Tokyo), 53, 755, 10.2176/nmc.ra2013-0200 Ostman, 2004, PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma, Cytokine Growth Factor Rev, 15, 4899, 10.1016/j.cytogfr.2004.03.002 Ostrom, 2013, CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010, Neuro Oncol, 15, ii1, 10.1093/neuonc/not151 Pan, 2012, A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma, J Neurooncol, 110, 111, 10.1007/s11060-012-0943-z Peereboom, 2013, NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme, Neuro Oncol, 15, 490, 10.1093/neuonc/nos322 Pelloski, 2006, Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma, Clin Cancer Res, 12, 3935, 10.1158/1078-0432.CCR-05-2202 Penuelas, 2009, TGF-beta increases glioma-initiating cell self renewal through the induction of LIF in human glioblastoma, Cancer Cell, 15, 315, 10.1016/j.ccr.2009.02.011 Phurphanich, 2010, Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma, J Neurooncol, 100, 95, 10.1007/s11060-010-0143-7 Pines, 2010, EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism, Oncogene, 29, 5850, 10.1038/onc.2010.313 Pitter, 2011, Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma, PLoS One, 6, e14545, 10.1371/journal.pone.0014545 Potts, 2011, Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials, Curr Cancer Drug Targets, 11, 254, 10.2174/156800911794519716 Prasad, 2011, Inhibition of PI3K/mTOR pathways in glioblastoma and implications in combination therapy with temozolomide, Neuro Oncol, 13, 384, 10.1093/neuonc/noq193 Quayle, 2012, Somatic mutations of PIK3R1 promote gliomagenesis, PLoS One, 7, e49466, 10.1371/journal.pone.0049466 Quinn, 2009, Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma, J Clin Oncol, 27, 1262, 10.1200/JCO.2008.18.8417 Raizer, 2009, A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy, Neuro Oncol, 22, 133 Rassi, 2013, Bosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia, Pharmacogenomics and Pers Med, 6, 57 Raymond, 2008, Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study, J Clin Oncol, 26, 4659, 10.1200/JCO.2008.16.9235 Razis, 2009, Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment, Clin Cancer Res, 15, 6258, 10.1158/1078-0432.CCR-08-1867 Reardon, 2011, Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy, J Neurooncol, 103, 371, 10.1007/s11060-010-0403-6 Reardon, 2010, Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma, J Neurooncol, 96, 219, 10.1007/s11060-009-9950-0 Reardon, 2009, Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma, Br J Cancer, 101, 119, 10.1038/sj.bjc.6605411 Reardon, 2009, Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma, Cancer, 115, 2188, 10.1002/cncr.24213 Reardon, 2005, Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme, J Clin Oncol, 23, 9359, 10.1200/JCO.2005.03.2185 Reardon, 2008, Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in patients with recurrent glioblastoma multiforme, J Clin Oncol, 26, 5610, 10.1200/JCO.2008.16.7510 Reardon, 2013, A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma, Clin Cancer Res, 19, 900, 10.1158/1078-0432.CCR-12-1707 Reardon, 2008, Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme, Expert Opin Investig Drugs, 17, 1225, 10.1517/13543784.17.8.1225 Reardon, 2006, Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma, Clin Cancer Res, 12, 860, 10.1158/1078-0432.CCR-05-2215 Reardon, 2011, Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma, J Neurooncol, 105, 621, 10.1007/s11060-011-0631-4 Reardon, 2011, Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma, J Neurooncol, 101, 57, 10.1007/s11060-010-0217-6 Reardon, 2012, Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma, J Neurooncol, 108, 499, 10.1007/s11060-012-0848-x Reardon, 2012, Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial, Cancer Chemother Pharmacol, 69, 849, 10.1007/s00280-011-1773-y Ribot, 2007, Microglia used as vehicles for both inducible thymidine kinase gene therapy and MRI contrast agents for glioma therapy, Cancer Gene Ther, 14, 724, 10.1038/sj.cgt.7701060 Rich, 2004, Phase II trial of gefitinib in recurrent glioblastoma, J Clin Oncol, 22, 133, 10.1200/JCO.2004.08.110 Rich, 2005, A phase I trial of gefitinib (ZD1 839) plus rapamycin for patients with recurrent malignant glioma, J Clin Oncol, 23, 10.1200/jco.2005.23.16_suppl.1565 Robins, 2006, Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021, Neuro Oncol, 8, 47, 10.1215/S1522851705000311 Rosenfeld, 2010, A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma, Neuro Oncol, 12, 1071, 10.1093/neuonc/noq071 Sai, 2012, Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway, J Neurooncol, 107, 487, 10.1007/s11060-011-0786-z Sampson, 2010, Immonulogic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma, J Clin Oncol, 28, 422, 10.1200/JCO.2010.28.6963 Sarangi, 2009, Targeted inhibition of the Hedgehog pathway in established malignant glioma cells enhances survival, Oncogene, 28, 3468, 10.1038/onc.2009.208 Sarkaria, 2010, Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks, Clin Cancer Res, 16, 5573, 10.1158/1078-0432.CCR-10-1453 Sarkaria, 2011, North Central Cancer Treatment group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme, Int J Radiat Oncol Biol Phys, 81, 468, 10.1016/j.ijrobp.2010.05.064 Sasine, 2010, Topoisomerase I inhibitors in the treatment of primary CNS malignancies: an update on recent trends, Anticancer Agents Med Chem, 10, 683, 10.2174/187152010794479825 Sathornsumetee, 2010, Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma, Neuro Oncol, 12, 1300, 10.1093/neuonc/noq099 Sathornsumetee, 2007, Molecularly targeted therapy for malignant glioma, Cancer, 110, 13, 10.1002/cncr.22741 Sauvageot, 2009, Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells, Neuro Oncol, 11, 109, 10.1215/15228517-2008-060 Sawada, 1998, Brain specific gene expression by immortalized microglial cell-mediated gene transfer in the mammalian brain, FEBS Lett, 433, 37, 10.1016/S0014-5793(98)00879-5 Schmidt, 2006, PCV chemotherapy for recurrent glioblastoma, Neurology, 66, 587, 10.1212/01.wnl.0000197792.73656.c2 Schmidt, 2008, L1 and CAM adhesion molecules as signaling coreceptors in neuronal migration and process outgrowth, Curr Opin Neurobiol, 18, 245, 10.1016/j.conb.2008.07.015 Schwartzbaum, 2006, Epidemiology and molecular pathology of glioma, Nat Clin Pract Neurol, 2, 494, 10.1038/ncpneuro0289 Scott, 1998, Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-96, Int J Radiat Oncol Biol Phys, 40, 51, 10.1016/S0360-3016(97)00485-9 Sebti, 2004, Farnesyltransferase inhibitors, Semin Oncol, 31, 28, 10.1053/j.seminoncol.2003.12.012 See, 2011, Heat shock protein-peptide complex in the treatment of glioblastoma, Expert Rev Vaccines, 10, 721, 10.1586/erv.11.49 Shah, 2010, Rationale for the development of IMC-3G3, a fully human immunoglobulin subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha, Cancer, 116, 1018, 10.1002/cncr.24788 Sharma, 2012, Farnesyltransferase inhibitor manumycin targets IL1β-Ras-HIF-1α axis in tumor cells of diverse origin, Inflammation, 35, 516, 10.1007/s10753-011-9340-6 Shen, 2013, Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma, Br J Cancer, 109, 164, 10.1038/bjc.2013.306 Sheppard, 2012, Targeting PI3 kinase/AKT/mTOR signaling in cancer, Crit Rev Oncog, 17, 69, 10.1615/CritRevOncog.v17.i1.60 Shinojima, 2003, Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme, Cancer Res, 63, 6962 Sierra, 2011, c-MET as a potential therapeutic target and biomarker in cancer, Ther Adv Med Oncol, 3, s21, 10.1177/1758834011422557 Solomón, 2013, Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial, BMC Cancer, 13, 299, 10.1186/1471-2407-13-299 Spence, 2004, Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas, J Neurooncol, 70, 91, 10.1023/B:NEON.0000040837.68411.97 Stockhausen, 2012, Notch signaling and brain tumors, Adv Exp Med Biol, 727, 289, 10.1007/978-1-4614-0899-4_22 Stupp, 2009, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, 10, 459, 10.1016/S1470-2045(09)70025-7 Stupp, 2010, Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma, J Clin Oncol, 28, 2712, 10.1200/JCO.2009.26.6650 Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330 Stupp, 2010, High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow up, Ann Oncol, 5, 190, 10.1093/annonc/mdq187 Tabatabai, 2010, Targeting integrins in malignant glioma, Target Oncol, 5, 175, 10.1007/s11523-010-0156-3 Tamura, 2012, Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma lines, Anticancer Res, 32, 4823 Terasaki, 2011, Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen – A24 with recurrent or progressive glioblastoma multiforme, J Clin Oncol, 29, 337, 10.1200/JCO.2010.29.7499 Thiesen, 2010, A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation, Cancer Chemother Pharmacol, 65, 353, 10.1007/s00280-009-1041-6 Tsuzuki, 1998, Neural cell adhesion molecule L1 in gliomas: correlation with TGF-beta and p53, J Clin Pathol, 51, 13, 10.1136/jcp.51.1.13 Tzadok, 2010, In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells, Int J Oncol, 37, 1043 van den Bent, 2009, Randomized trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034, J Clin Oncol, 27, 1268, 10.1200/JCO.2008.17.5984 Verhaak, 2010, Intergrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1, Cancer Cell, 17, 98, 10.1016/j.ccr.2009.12.020 Villano, 2009, Temozolomide in malignant gliomas: current use and future targets, Cancer Chemother Pharmacol, 64, 647, 10.1007/s00280-009-1050-5 Vlachostergios, 2013, Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner, Invest New Drugs, 31, 1169, 10.1007/s10637-013-9968-1 Wang, 2012, Brain distribution of cediranib is limited by active efflux at the blood-brain barrier, J Pharmacol Exp Ther, 341, 386, 10.1124/jpet.111.190488 Wang, 2010, Sonic Hedgehog/GLI1 signalling pathway inhibition restricts cell migration and invasion in human gliomas, Neurol Res, 32, 975, 10.1179/016164110X12681290831360 Wang, 2014, Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients, Asia Pac J Clin Oncol Welsh, 2009, The c-Met receptor tyrosine kinase inhibitor MP470, radiosensitizes glioblastoma cells, Radiat Oncol, 4, 69, 10.1186/1748-717X-4-69 Wen, 2010, American Society of Clinical Oncology 2010: report of selected studies from the CNS tumor section, Expert Rev Anticancer Ther, 10, 1367, 10.1586/era.10.117 Wen, 2009, Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02), ASCO Meet Abstr, 27, 2006 Wen, 2008, Malignant gliomas in adults, N Engl J Med, 359, 492, 10.1056/NEJMra0708126 Wen, 2011, A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma, Neuro Oncol, 13, 437, 10.1093/neuonc/noq198 Wen, 2006, Medical management of patients with brain tumors, J Neurooncol, 80, 131, 10.1007/s11060-006-9193-2 Wen, 2006, Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08, Clin Cancer Res, 2, 4899, 10.1158/1078-0432.CCR-06-0773 Wick, 2010, Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma, J Clin Oncol, 28, 1168, 10.1200/JCO.2009.23.2595 Wick, 2013, Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation, Neuro Oncol, 15, 1405, 10.1093/neuonc/not100 Wick, 2011, Pathway inhibition: emerging molecular targets for treating glioblastoma, Neuro Oncol, 13, 566, 10.1093/neuonc/nor039 Wieland, 2013, Anticancer effects of niclosamide in human glioblastoma, Clin Cancer Res, 19, 4124, 10.1158/1078-0432.CCR-12-2895 Wilson, 2014, Glioblastoma multiforme: State of the art and future therapeutics, Surg Neurol Int, 5, 64, 10.4103/2152-7806.132138 Wood, 2009, Vitespen: a preclinical and clinical review, Future Oncol, 5, 763, 10.2217/fon.09.46 Wrensch, 2002, Epidemiology of primary brain tumors: current concepts and review of the literature, Neuro Oncol, 4, 278, 10.1093/neuonc/4.4.278 Xie, 2012, Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma, Proc Natl Acad Sci U S A, 109, 570, 10.1073/pnas.1119059109 Yakes, 2011, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth, Mol Cancer Ther, 10, 2298, 10.1158/1535-7163.MCT-11-0264 Yarden, 2001, Untangling the ErbB signaling network, Nat Rev Mol Cell Biol, 2, 127, 10.1038/35052073 Ye, 2012, Therapeutic targeting of EGFR in malignant gliomas, Expert Opin Ther Targets, 14, 303, 10.1517/14728221003598948 Yelskaya, 2013, Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa, PLoS One, 8, e64588, 10.1371/journal.pone.0064588 Yiin, 2010, ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain, Mol Cancer Ther, 9, 929, 10.1158/1535-7163.MCT-09-0953 Yin, 2014, Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signallling, Oncol Rep, 32, 1610, 10.3892/or.2014.3342 Yust-Katz, 2013, Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or TMZ refractory glioblastoma, Cancer, 2013, 2747, 10.1002/cncr.28031 Zanotto-Filho, 2012, Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling, Invest New Drugs, 30, 2252, 10.1007/s10637-012-9804-z Zhang, 2011, Trimodal gioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor kinase inhibitor LY2109761, Neoplasia, 13, 537, 10.1593/neo.11258 Zhang, 2011, Blockade of TGF-β signaling by the TGFRβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma, Cancer Res, 71, 7155, 10.1158/0008-5472.CAN-11-1212 Zhang, 2012, Temozolomide: mechanisms of action, repair and resistance, Curr Mol Pharmacol, 5, 102, 10.2174/1874467211205010102 Zhao, 2011, Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity, Clin Cancer Res, 17, 771, 10.1158/1078-0432.CCR-10-2444 Zhuang, 2012, Curcumin promotes differentiation of glioma-initiating cells by inducing autophagy, Cancer Science, 103, 684, 10.1111/j.1349-7006.2011.02198.x Zou, 2013, Gamma secretase inhibitor DAPT suppresses glioblastoma growth via uncoupling of tumor vessel density from vessel function, Clin Exp Med, 13, 271, 10.1007/s10238-012-0203-8